Drug Interactions and the Cytochrome P450 System. The Role of Cytochrome P450 1A2
作者： Kim Brøsen , None
DOI: 10.2165/00003088-199500291-00005
关键词:
摘要: Cytochrome P450 1A2 (CYP1A2) accounts for about 10 to 15% of the total CYP content human liver and is major enzyme involved in metabolism imipramine, propranolol, clozapine, theophylline, caffeine. It also conversion heterocyclic amines their proximal carcinogenic mutagenic forms, as well endogenous substances, including 17β-estradiol uroporphyrinogen III. Fluvoxamine a potent inhibitor CYP1A2, there potential interaction with drugs that are metabolised by this isoenzyme. This property fluvoxamine may be usefully applied identifying agents substrates it has possible therapeutic application prevention CYP1A2-mediated toxic metabolite formation.
springer.com
sci-hub.se 参考文章(19)
K. Br�sen, The pharmacogenetics of the selective serotonin reuptake inhibitors. Journal of Molecular Medicine. ,vol. 71, pp. 1002- 1009 ,(1993) , 10.1007/BF00180032
Alan R Boobis, Anthony M Lynch, Stephen Murray, Rafael de la Torre, Anna Solans, M Farré, Jorde Segura, Nigel J Gooderham, Donald S Davies, CYP1A2-catalyzed Conversion of Dietary Heterocyclic Amines to Their Proximate Carcinogens Is Their Major Route of Metabolism in Humans Cancer Research. ,vol. 54, pp. 89- 94 ,(1994)
C Sengstag, H P Eugster, F E Würgler, M Probst, Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae. Drug Metabolism and Disposition. ,vol. 21, pp. 43- 49 ,(1993)
Kim Brøsen, Lars F. Gram, Per Kragh-Sørensen, Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin. Therapeutic Drug Monitoring. ,vol. 13, pp. 177- 182 ,(1991) , 10.1097/00007691-199103000-00015
Kim Brøsen, Erik Skjelbo, Birgitte B. Rasmussen, Henrik E. Poulsen, Steffen Loft, Fluvoxamine is a potent inhibitor of cytochrome P4501A2 Biochemical Pharmacology. ,vol. 45, pp. 1211- 1214 ,(1993) , 10.1016/0006-2952(93)90272-X
Markus Jerling, Leif Lindström, Ulf Bondesson, Leif Bertilsson, Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Therapeutic Drug Monitoring. ,vol. 16, pp. 368- 374 ,(1994) , 10.1097/00007691-199408000-00006
F. Peter Guengerich, Dong Hyun Kim, Masahiko Iwasaki, Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects Chemical Research in Toxicology. ,vol. 4, pp. 168- 179 ,(1991) , 10.1021/TX00020A008
David C. Spink, Hans-Pietro Eugster, David W. Lincoln, John D. Schuetz, Erin G. Schuetz, Judith A. Johnson, Laurence S. Kaminsky, John F. Gierthy, 17β-Estradiol hydroxylation catalyzed by human cytochrome P450 1A1: A comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA☆ Archives of Biochemistry and Biophysics. ,vol. 293, pp. 342- 348 ,(1992) , 10.1016/0003-9861(92)90404-K
Ami D. Sperber, Toxic Interaction Between Fluvoxamine and Sustained Release Theophylline in an 11-Year-Old Boy Drug Safety. ,vol. 6, pp. 460- 462 ,(1991) , 10.2165/00002018-199106060-00006
L Bertilsson, JA Carrillo, ML Dahl, A Llerena, C Alm, U Bondesson, L Lindstrom, I Rodriguez de la Rubia, S Ramos, J Benitez, Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. British Journal of Clinical Pharmacology. ,vol. 38, pp. 471- 473 ,(1994) , 10.1111/J.1365-2125.1994.TB04385.X